Traws Pharma, Inc. (TRAW) director awarded RSUs and stock options in 2025 grant

Rhea-AI Filing Summary

Traws Pharma, Inc. director Werner Cautreels reported equity awards dated 12/12/2025. He received 4,874 restricted stock units at a price of $0, increasing his directly held common stock to 109,222 shares.

He was also granted stock options for 19,496 shares of common stock at an exercise price of $2.33, expiring 12/12/2035. The restricted stock units and the options each vest 100% on the first anniversary of the grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider CAUTREELS WERNER

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to purchase)	19,496	$0.00	--
Grant/Award	Common Stock	4,874	$0.00	--

Holdings After Transaction: Stock Option (right to purchase) — 19,496 shares (Direct); Common Stock — 109,222 shares (Direct)

Footnotes (1)

1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis. The options vest 100% on the first anniversary of the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAUTREELS WERNER

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		4,874(1)	A	$0	109,222	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$2.33	12/12/2025		A		19,496		12/12/2026(2)	12/12/2035	Common Stock	19,496	$0	19,496	D

Explanation of Responses:

1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

2. The options vest 100% on the first anniversary of the grant date.

	/s/ Werner Cautreels	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the Traws Pharma (TRAW) insider involved in this transaction?

The reporting person is Werner Cautreels, identified as a director of Traws Pharma, Inc.

What equity awards did Traws Pharma (TRAW) grant on 12/12/2025?

On 12/12/2025, the director received 4,874 restricted stock units of common stock at a price of $0 and a stock option for 19,496 shares of common stock at an exercise price of $2.33.

When do the Traws Pharma (TRAW) restricted stock units vest?

The 4,874 restricted stock units vest 100% on the first anniversary of the grant date, and each unit converts into one share of common stock.

What are the terms of the stock options granted to the Traws Pharma (TRAW) director?

The director received stock options for 19,496 shares of common stock with an exercise price of $2.33, vesting 100% on the first anniversary of the grant date and expiring on 12/12/2035.

How many Traws Pharma (TRAW) shares does the director own after this transaction?

Following the reported awards, the director beneficially owns 109,222 shares of common stock directly and 19,496 derivative securities related to the stock options.